This paper is only available as a PDF. To read, Please Download here.
Traditionally, drug therapy for benign prostatic hyperplasia (BPH) has been reserved for patients with mild or moderate symptoms. The objective of this analysis was to compare responses to an alpha1-adrenergic receptor blocker, doxazosin, in patients with severe, intermediate, and mild disease. Data were analyzed from patients with symptomatic BPH who were enrolled in two 16-week, double-masked, placebo-controlled studies of doxazosin. In study 1, 163 hypertensive patients were stratified according to baseline maximum (Qmax) and mean (Qmean) urinary flow rate as having severe, intermediate, or mild disease. In study 2, 82 normotensive patients were stratified according to their baseline American Urological Association (AUA) BPH symptom severity score and modified Boyarsky symptom bothersomeness score. Overall, doxazosin was significantly more effective than placebo in improving Qmax and Qmean in study 1 and in improving the AUA-derived and modified Boyarsky scores in study 2. There were statistically significant differences in the response to treatment, as represented by Qmax, Qmean, and modified Boyarsky score, between patients with severe, intermediate, and mild disease. There were no significant differences in the AUA-derived scores of patients in the three severity groups. These results have important clinical implications, suggesting that the majority of BPH patients are candidates for a course of drug therapy, regardless of baseline disease status.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Therapeutics
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Transurethral resection of the prostate among Medicare beneficiaries in the United States: Time trends and outcomes.Urology. 1994; 44: 692-698
- Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States.J Urol. 1995; 154: 205-206
- Benign Prostatic Hyperplasia: Diagnosis and Treatment. Quick Reference Guide for Clinicians. Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, Rockville, MD1994 (AHCPR Publication No. 94-0583)
- Recommendations of the International Consensus Committee.in: Cockett ATK Khoury S Aso Y Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). Scientific Communication International Ltd, Jersey, UK1996: 625-640
- Effect of demographic factors, urine peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia.Urology. 1995; 45: 398-405
- Men's Experience and Knowledge Concerning Enlarged Prostate. The Gallup Organization, Princeton, NJ1989 (Report No. G089206)
- Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo-controlled, dose-response multicenter study.J Urol. 1995; 154: 110-115
- Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study.J Urol. 1995; 154: 105-109
- Using repeated measures of symptom score, uroflowmetry and PSA in the clinical management of prostatic disease.J Urol. 1995; 153: 99-103
- The American Urological Association symptom index for benign prostatic hyperplasia.J Urol. 1992; 148: 1549-1557
- A new look at bladder neck obstruction by the Food and Drug Administration regulators: Guidelines for investigation of benign prostatic hypertrophy.Trans Am Assoc Genito-Urin Surg. 1977; 68: 29-32
- The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: Prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume.Br J Urol. 1995; 75: 622-630
- Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia.J Urol. 1993; 150: 351-358
- Safety and efficacy of doxazosin in benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies.Urology. 1996; 48: 406-415
- Prostate volume predicts outcome of treatment of BPH with finasteride: Meta-analysis of randomized clinical trials.J Urol. 1996; 155 (Abstract 1044): 572A
- Tests which predict outcome following transurethral resection of the prostate.J Urol. 1996; 155 (Abstract 1049): 573A
© 1998 Published by Elsevier Inc.